Key result
Stopping oral anticoagulants in patients with residual vein thrombosis yielded a recurrent event rate of 27.2% compared to 19.3% with continuation (HR 1.58; 95% CI 0.85-2.93; P=0.145).
Why the study?
Does continuing oral anticoagulants for 9 additional months reduce recurrent venous thromboembolism and/or major bleeding in patients with a first episode of deep vein thrombosis and residual vein thrombosis?
Population
258 patients with a first episode of deep vein thrombosis, treated with oral anticoagulant treatment for 3…
Comparison
Continuing oral anticoagulants for 9 additional… vs Stopping oral anticoagulants
Design
RCT, randomized
Authors
Loading...
Does not support routine continuation after residual vein thrombosis; leaves open ultrasound-guided duration after first DVT.
RCT (n=258)
randomized
Does continuing oral anticoagulants for 9 additional months reduce recurrent venous thromboembolism and/or major bleeding in patients with a first episode of deep vein thrombosis and residual vein thrombosis?
Effect estimate: HR 1.58 (95% CI 0.85-2.93)
Absolute Event Rate: 27.2% vs 19.3%
p-value: p=.145
Absence of residual vein thrombosis on ultrasound after 3 months of anticoagulation for a first DVT identifies a low-risk group that can safely discontinue therapy.
Siragusa et al. (2008) conducted an RCT in deep vein thrombosis (n=258). stop anticoagulants vs. continue anticoagulants was evaluated on recurrent venous thromboembolism and/or major bleeding (HR 1.58, 95% CI 0.85-2.93, p=.145). Stopping oral anticoagulants in patients with residual vein thrombosis yielded a recurrent event rate of 27.2% compared to 19.3% with continuation (HR 1.58; 95% CI 0.85-2.93; P=0.145).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: